Australia New Zealand Gynaecological Oncology Group
17
7
7
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
23.5%
4 terminated/withdrawn out of 17 trials
42.9%
-43.6% vs industry average
41%
7 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Role: collaborator
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Role: collaborator
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Role: collaborator
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Role: collaborator
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
Role: collaborator
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Role: lead
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Role: collaborator
Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)
Role: collaborator
Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
Role: collaborator
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Role: lead
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Role: lead
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Role: collaborator
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
Role: collaborator
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Role: collaborator
An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
Role: collaborator
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
Role: collaborator
Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer
Role: collaborator
All 17 trials loaded